Xtant Medical Holdings, Inc.
NYSEAM:XTNT Lagerbericht
Marktkapitalisierung: US$74.9m
Xtant Medical Holdings Ausschüttungen und Rückkäufe
Zukünftiges Wachstum Kriterienprüfungen 0/6 Xtant Medical Holdings hat in der Vergangenheit keine Dividende gezahlt.
Wichtige Informationen
n/a
Dividendenausschüttung
Gesamte Aktionärsrendite -18.3% Zukünftige Dividendenrendite n/a Wachstum der Dividende n/a Nächster Dividendenzahlungstermin n/a Ex-Dividendendatum n/a Dividende pro Aktie n/a Ausschüttungsquote n/a
Jüngste Updates zu Dividenden und Rückkäufen
Alle Updates anzeigen
Xtant Medical Holdings, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
Consensus EPS estimates fall by 11% Oct 20
New minor risk - Profitability Oct 18
Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System Sep 24
Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus Sep 18 Xtant Medical Holdings, Inc. announced that it has received $5 million in funding Aug 13
New minor risk - Shareholder dilution Aug 11
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024 Aug 09 Xtant Medical Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024 Jun 13
New minor risk - Profitability Jun 07
Price target increased by 27% to US$2.35 May 30
Consensus EPS estimates fall by 33% May 22
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 17
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024 May 17
Xtant Medical Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024 May 10
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds May 01
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds Apr 30
Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Apr 03
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 02
Xtant Medical Holdings, Inc. to Report Q4, 2023 Results on Apr 01, 2024 Mar 22
Investor sentiment improves as stock rises 22% Feb 28
New minor risk - Share price stability Feb 24
Investor sentiment improves as stock rises 17% Feb 07
Investor sentiment improves as stock rises 15% Nov 28
Consensus revenue estimates increase by 17% Nov 16
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 10
Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023 Nov 10
Xtant Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Consensus EPS estimates fall by 17%, revenue upgraded Aug 08
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023 Aug 03
Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat Aug 02
Xtant Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 26
Consensus EPS estimates upgraded to US$0.06 loss Jul 12 Xtant Medical Holdings, Inc. announced that it expects to receive $15 million in funding Jul 04
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Jun 21
Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors May 19
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 06
Xtant Medical Holdings, Inc. Announces Executive Changes May 06
Xtant Medical Holdings, Inc. Provides Revenue Guidance for the Full Year 2023 May 05
Full year 2022 earnings released: US$0.09 loss per share (vs US$0.057 loss in FY 2021) Mar 09
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023 Feb 02
Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023 Jan 10
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.021 loss in 3Q 2021) Nov 04
Xtant Medical Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Xtant Medical Holdings, Inc., Annual General Meeting, Oct 26, 2022 Sep 01 Xtant Medical Holdings, Inc. announced that it expects to receive $9.746606 million in funding
Second quarter 2022 earnings released: US$0.02 loss per share (vs US$0.008 loss in 2Q 2021) Aug 05
Xtant Medical Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 06
Xtant Medical Holdings, Inc. Announces the Appointment of Scott Neils as Chief Financial Officer, Effective June 1, 2022 May 03
Less than half of directors are independent Apr 27
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 10
Xtant Medical Holdings, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Mar 03
Third quarter 2021 earnings released: US$0.021 loss per share (vs US$0.10 loss in 3Q 2020) Nov 14
Second quarter 2021 earnings released: US$0.008 loss per share (vs US$0.19 loss in 2Q 2020) Aug 10
Shareholders Are Thrilled That The Xtant Medical Holdings (NYSEMKT:XTNT) Share Price Increased 186% Mar 02
New 90-day high: US$4.26 Feb 27
Xtant Medical Holdings, Inc. announced that it has received $20.000003 million in funding Feb 26
Full year 2020 earnings released: US$0.25 loss per share (vs US$0.63 loss in FY 2019) Feb 26
Xtant Medical Holdings, Inc. announced that it expects to receive $20.000003 million in funding Feb 24
Xtant Medical Holdings, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: US$1.84 Feb 10
New 90-day high: US$1.52 Jan 22
Third quarter earnings released Oct 30
Third-quarter earnings released: Earnings beat expectations, revenue disappoints Oct 30
New 90-day high: US$1.63 Oct 17
Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards Oct 07 Xtant Medical Holdings, Inc. announced that it expects to receive $62.882 million in funding
New 90-day low: US$0.76 Sep 26
New 90-day low - US$0.87 Sep 03
First half earnings released Aug 05
Xtant Medical Holdings, Inc. to Report Q2, 2020 Results on Aug 03, 2020 Jul 31
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Growth Index Jul 05
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Index Jul 02
Stabilität und Wachstum des Zahlungsverkehrs
Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von XTNT in der Vergangenheit stabil war.
Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von XTNT gestiegen sind.
Dividendenrendite im Vergleich zum Markt Xtant Medical Holdings Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von XTNT im Vergleich zum Markt aus? Segment Dividendenrendite Unternehmen (XTNT) n/a Untere 25 % des Marktes (US) 1.4% Markt Top 25 % (US) 4.3% Branchendurchschnitt (Medical Equipment) 1.7% Analystenprognose (XTNT) (bis zu 3 Jahre) n/a
Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von XTNT im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.
Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von XTNT im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von XTNT, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da XTNT keine Ausschüttungen gemeldet hat.
Entdecken Sie dividendenstarke Unternehmen Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
